FutureHouse's Robin system proposes ripasudil as a candidate dry AMD treatment

FutureHouse/AI Scientist platform

FutureHouse's Robin, a multi-agent system, proposed ripasudil (a glaucoma drug) as a treatment for dry age-related macular degeneration, and lab tests on human retinal cells showed it boosted debris clearing. Humans ran experiments, but Robin generated hypotheses, designs and analyses; the work took 2.5 months.

• Robin combines three agents: Crow (literature review), Falcon (candidate assessment), Finch (data analysis).
• Proposed ripasudil (Rho-kinase inhibitor used for glaucoma) for dry AMD.
• Hypothesis: enhancing retinal pigment epithelium phagocytosis benefits dry AMD.
• Results validated in human retinal cell cultures; humans performed physical lab work.